rs1114167767
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000179.3(MSH6):c.3477delC(p.Tyr1159fs) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000179.3 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
This variant deletes 1 nucleotide in exon 6 of the MSH6 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH6 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
The c.3477delC pathogenic mutation, located in coding exon 6 of the MSH6 gene, results from a deletion of one nucleotide at nucleotide position 3477, causing a translational frameshift with a predicted immediate stop codon (p.Y1159*). This pathogenic mutation has been reported in an individual diagnosed with colon cancer at age 59 whose tumor showed high microsatellite instability and absent MSH6 expression on IHC (van Lier MG et al. J. Pathol. 2012 Apr;226(5):764-74). This mutation was also identified in an Ashkenazi Jewish woman with endometrial and pancreatic cancers whose family history met Amsterdam II criteria (Yablonski-Peretz T et al. Breast Cancer Res. Treat. 2016 Jan;155(1):133-8). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Lynch syndrome 5 Pathogenic:1
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
Hereditary nonpolyposis colon cancer Pathogenic:1
Variant summary: MSH6 c.3477delC (p.Tyr1159X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (eg. c.3514dupA (p.Arg1172fsX5), c.3991C>T (p.Arg1331X)). The variant was absent in 251396 control chromosomes (gnomAD) but has been reported in the literature in individuals affected with colorectal cancer, endometrium cancer and pancreatic cancer (e.g. vanLier_2012, Yablonski-Peretz_2015). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two other variants with a different nucleotide change (c.3477C>A and c.3477C>G) resulting in same truncation (p.Tyr1159X) have been reported as pathogenic/likely pathogenic by us and others in ClinVar. Two ClinVar submitters (evaluation after 2014) cite this variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
not provided Pathogenic:1
This frameshift variant alters the translational reading frame of the MSH6 mRNA and causes the premature termination of MSH6 protein synthesis. It has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). In the published literature, the variant has been identified in individuals with colorectal cancer (PMID: 22081473 (2012)) and endometrial/pancreatic cancer (PMID: 26687385 (2016)). Based on the available information, this variant is classified as pathogenic. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Tyr1159*) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with colorectal, endometrial, and pancreatic cancers (PMID: 22081473, 26687385). Invitae Evidence Modeling of clinical and family history, age, sex, and reported ancestry of multiple individuals with this MSH6 variant has been performed. This variant is expected to be pathogenic with a positive predictive value of at least 99%. This is a validated machine learning model that incorporates the clinical features of 1,370,736 individuals referred to our laboratory for MSH6 testing. ClinVar contains an entry for this variant (Variation ID: 428395). For these reasons, this variant has been classified as Pathogenic. -
Endometrial carcinoma Pathogenic:1
_x000D_ Criteria applied: PVS1, PS4_MOD, PM2_SUP -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at